2025
Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk Management
Wahood S, Alani O, Draw I, Shqair L, Wang D, Bunick C, Damiani G, Ho J, Obagi S, Akbarialiabad H, Galimberti F, Ghannoum M, Grada A. Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk Management. Pharmaceuticals 2025, 18: 800. PMID: 40573197, PMCID: PMC12196204, DOI: 10.3390/ph18060800.Peer-Reviewed Original ResearchSoft tissue infectionsTissue infectionsMultidrug-resistant Gram-negative organismsRisk of torsade de pointesClinical useLiterature search of PubMedResistant to ciprofloxacinComplicated skin infectionsHigh-risk patientsQT interval prolongationCorrected QT IntervalShort treatment courseGram-negative organismsPatient risk factorsSearch of PubMedBacterial skinOral fluoroquinolonesInterval prolongationTreatment courseOral formulationResistance patternsCure rateQT intervalTopical treatmentSkin infectionsP-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
Kalyatanda G, Dousa K, Lyons H, Mardourian M, Rhodes J, Iakovidis A, El-Helou G, Wilson B, Daley C, Holland S, Kreiswirth B, Nguyen D, Shin E, Kurz S, Johnson J, Bonomo R. P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients. Open Forum Infectious Diseases 2025, 12: ofae631.1672. PMCID: PMC11778049, DOI: 10.1093/ofid/ofae631.1672.Peer-Reviewed Original ResearchSubspecies abscessusB-lactamAssociated with high cure ratesIn vitro susceptibility resultsMulti-drug regimensCurrent treatment regimensSolid organ transplantationHigh cure ratesTime to initiationOptimize treatment outcomesMab infectionSynergy testClinical cureImmunocompromised patientsPulmonary infectionDiscontinued treatmentTreatment regimensCase reportClinical outcomesCure rateImmunocompromised individualsAutoimmune diseasesTreatment successEarly treatmentCulture conversion
2024
Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).
Xu Y, Lim Y, Bordeaux J, Aasi S, Alam M, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Grekin R, Mark L, Nehal K, Nghiem P, Olino K, Patel T, Scott J, Shaha A, Srivastava D, Schmults C. Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 39536442, DOI: 10.6004/jnccn.2024.7037.Peer-Reviewed Original ResearchConceptsMargin assessmentCell carcinomaNCCN guidelinesHigh-risk basal cell carcinomasCutaneous squamous cell carcinomaDeep margin assessmentMohs micrographic surgerySquamous cell carcinomaBasal cell carcinomaNonmelanoma skin cancerMicrographic surgeryDermatofibrosarcoma protuberansCure rateOptimal patient outcomesUninvolved tissueAccurate resectionSkin cancerPatient outcomesNCCNCarcinomaHistological visualizationMarginal surfacesTissueCCPDMAResectionAn unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia
Cai Y, Jiang H, Li T, Luo D, Li P, Wang Y. An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia. Heliyon 2024, 10: e37906. PMID: 39323819, PMCID: PMC11422042, DOI: 10.1016/j.heliyon.2024.e37906.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaProstate diseaseProstatic hyperplasiaBurkholderia pseudomallei</i>.Urine culturePulmonary infectionTrimethoprim-sulfamethoxazoleSurvival rate of patientsTreated with imipenemUrinary tract infectionAnti-infective treatmentRate of patientsHistory of hypertensionYear old maleMultiple organ damageProstatic abscessTract infectionsInflammatory markersClinical manifestationsCure rateUnusual caseFatal infectious diseaseOrgan damageDifficulty urinatingSurvival ratePatients with a history of more than one cancer diagnosis: An opportunity to expand eligibility criteria?
Campos L, Peguero J, Koontz M, Trotter C, Svedman C, Paulson J, Chung W, Tucker V, McAneny B, Campbell Fontaine A. Patients with a history of more than one cancer diagnosis: An opportunity to expand eligibility criteria? Journal Of Clinical Oncology 2024, 42: e23019-e23019. DOI: 10.1200/jco.2024.42.16_suppl.e23019.Peer-Reviewed Original ResearchMedian ageCancer diagnosisIncreasing proportion of elderly patientsProportion of elderly patientsMedian time intervalHistory of 2Early-stage cancerCommunity oncology sitesAnalyzed patientsClinical characteristicsNSCLC diagnosisCure rateElderly patientsGenomic alterationsClinical trialsNSCLCPatientsExclusion criteriaCancerOncology sitesLonger life expectancyDiagnosisEligibility criteriaTesting ratesLife expectancy
2023
The effect of single dose albendazole (400 mg) treatment on the human gut microbiome of hookworm-infected Ghanaian individuals
Appiah-Twum F, Akorli J, Okyere L, Sagoe K, Osabutey D, Cappello M, Wilson M. The effect of single dose albendazole (400 mg) treatment on the human gut microbiome of hookworm-infected Ghanaian individuals. Scientific Reports 2023, 13: 11302. PMID: 37438457, PMCID: PMC10338455, DOI: 10.1038/s41598-023-38376-3.Peer-Reviewed Original ResearchConceptsHookworm infectionAlbendazole treatmentMicrobiota compositionStool samplesGut microbiomeGut microbiome dysbiosisInfection cure rateKintampo North MunicipalityPre-treatment statePotential microbial biomarkersAdjunct treatmentAnthelminthic therapySingle doseCure rateMicrobiome dysbiosisTreatment outcomesGut homeostasisPharmacological responseProbiotic supplementationGut microbiotaUninfected individualsCommensal bacteriaInfected individualsTherapy outcomeHuman gut microbiomeCutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study
del Mar Castro M, Rode J, Machado P, Llanos-Cuentas A, Hueb M, Cota G, Rojas I, Orobio Y, Sarmiento O, Rojas E, Quintero J, Pimentel M, Soto J, Suprien C, Alvarez F, Ramos A, dos Santos Arantes R, da Silva R, Arenas C, Vélez I, Lyra M, Saravia N, Arana B, Alexander N. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study. PLOS Neglected Tropical Diseases 2023, 17: e0011029. PMID: 36689465, PMCID: PMC9894540, DOI: 10.1371/journal.pntd.0011029.Peer-Reviewed Original ResearchConceptsCollaborative retrospective studyRetrospective studyAdverse reactionsCutaneous leishmaniasisAge groupsMedian lesion diameterOverall cure rateOlder adult patientsMost adverse reactionsCutaneous leishmaniasis treatmentYears of ageMonotherapy regimenAdult patientsReferral centerLocal therapyPediatric populationClinical recordsCure rateCL patientsTherapeutic responseClinical trialsDisease presentationMedian numberMild intensityAntileishmanial treatment
2022
Impact of early detection on cancer curability: A modified Delphi panel study
Schwartzberg L, Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk B, Wong D, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study. PLOS ONE 2022, 17: e0279227. PMID: 36542647, PMCID: PMC9770338, DOI: 10.1371/journal.pone.0279227.Peer-Reviewed Original ResearchConceptsBlood testsLikelihood of benefitCancer typesEarly detectionEarly cancer detectionSolid tumorsTotal cancer incidenceAmerican Joint CommitteeLow cure rateRAND/UCLAPotential clinical benefitCancer detectionDelphi panel studyLong cancerClinical benefitCure ratePotential benefitsCancer curabilityMost cancer typesCancer incidenceHigh curabilityJoint CommitteeTreat cancersExpert consensusPanel consensusNCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 322-334. PMID: 35390768, DOI: 10.6004/jnccn.2022.0021.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaNCCN guidelinesClassical HLNodular lymphocyte predominant Hodgkin lymphomaLymphocyte predominant Hodgkin lymphomaNCCN Guidelines InsightsModern treatment optionsManagement of patientsB-cell originClassical Hodgkin lymphomaLong-term toxicityUncommon malignancyCure rateTreatment optionsTreatment considerationsDose constraintsLymphomaRecent updatesGuidelinesPatientsMalignancy
2021
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discovery 2021, 11: candisc.1557.2020. PMID: 33941592, PMCID: PMC8598376, DOI: 10.1158/2159-8290.cd-20-1557.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerHER2 heterogeneityBreast cancerEarly-stage HER2-positive breast cancerHER2-positive early-stage breast cancerTherapeutic resistancePathologic complete response rateEarly-stage breast cancerNeoadjuvant clinical trialsComplete response rateSubset of patientsHER2 therapyPretreatment biopsiesEvaluable casesCure rateT-DM1Trastuzumab emtansineClinical trialsTreatment strategiesTreatment responseTreatment selectionResponse rateRelated commentaryTherapyIssue featurePediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL managementEstablishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy
Zuo S, Sun L, Wang Y, Chen B, Wang J, Ge X, Lu Y, Yang N, Shen P. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy. Cell Death & Disease 2021, 12: 208. PMID: 33627636, PMCID: PMC7904926, DOI: 10.1038/s41419-021-03499-w.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzoatesCell LineageCoculture TechniquesGene Expression Regulation, LeukemicHumansHydrazinesJanus KinasesK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice, NudeMitogen-Activated Protein KinasesPyrazolesReceptors, ThrombopoietinSignal TransductionSTAT Transcription FactorsThrombopoiesisUmbilical CordXenograft Model Antitumor AssaysConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsProgression of CMLCML cellsUC-MSCsDifferentiation therapyCurrent tyrosine kinase inhibitorsTherapeutic potentialMesenchymal stem cell treatmentAcute promyelocytic leukemia (APL) treatmentImmature white blood cellsSevere adverse effectsWhite blood cellsTrans retinoic acidStem cell treatmentStem/progenitor cellsComplete remissionTreatment regimenTumor burdenCML patientsCure rateMAPK signaling pathwaysPeripheral bloodHematopoietic stem/progenitor cellsMyeloid leukemiaChemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study
Pathak R, Canavan ME, Walters S, Salazar MC, Boffa DJ. Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study. Journal Of Thoracic Disease 2021, 13: 140-148. PMID: 33569194, PMCID: PMC7867841, DOI: 10.21037/jtd-20-1187.Peer-Reviewed Original ResearchEarly-stage esophageal cancerEsophageal cancerOverall survivalDefinitive non-surgical treatmentComorbidity-free patientsCT1/T2National Cancer DatabaseRetrospective cohort studyNon-surgical treatmentSubset of patientsGoals of careKaplan-Meier curvesNonsurgical treatment optionsKaplan-Meier estimatesInoperable patientsCohort studyNonsurgical approachCure rateTreatment optionsCancer patientsEndoscopic excisionCancer DatabaseTumor removalChemoradiationPatients
2019
Dose response and architecture in volume staged radiosurgery for large arteriovenous malformations: A multi-institutional study
Seymour ZA, Chan JW, Sneed PK, Kano H, Lehocky CA, Jacobs RC, Ye H, Chytka T, Liscak R, Lee CC, Yang HC, Ding D, Sheehan J, Feliciano CE, Rodriguez-Mercado R, Chiang VL, Hess JA, Sommaruga S, McShane B, Lee J, Vasas LT, Kaufmann AM, Grills I, McDermott MW. Dose response and architecture in volume staged radiosurgery for large arteriovenous malformations: A multi-institutional study. Radiotherapy And Oncology 2019, 144: 180-188. PMID: 31835173, DOI: 10.1016/j.radonc.2019.09.019.Peer-Reviewed Original ResearchConceptsLarge arteriovenous malformationsArteriovenous malformationsVS-SRSMargin doseObliteration rateVolume-staged stereotactic radiosurgeryMedian margin doseHigh-risk lesionsOptimal treatment paradigmAVM nidus volumeMulti-institutional studyImproved ratesCompact nidusEvaluable patientsMedian followRadiosurgical centersOverall survivalUpfront treatmentComplete responseMedian ageRetrospective reviewCure rateRare lesionsPrior embolizationTreatment paradigmStaying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs
Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade‐Nwulia O, Aspinall E, Hutchinson S, Hellard ME, Sacks‐Davis R. Staying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs. Liver International 2019, 39: 2244-2260. PMID: 31125496, DOI: 10.1111/liv.14152.Peer-Reviewed Original ResearchConceptsSustained viral responseDirect-acting antiviralsRecent PWIDOST recipientsTreatment discontinuationPerson yearsReinfection rateRelative riskTreatment outcomesSystematic reviewIncidence of reinfectionTreatment discontinuation ratesPooled relative riskHepatitis C treatmentNewcastle-Ottawa ScaleMixed effects linear modelTherapy recipientsDiscontinuation ratesHepatitis C.Pooled incidenceViral responseCure rateRecent injectingStudy qualityPWIDPoint/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.Peer-Reviewed Original ResearchConceptsDe-escalate treatmentOropharyngeal carcinomaHPV-positive oropharyngeal carcinomaNeck cancer clinical researchNew systemic agentsPhase II trialPhase III trialsTreatment-related morbidityHigh cure ratesCancer clinical researchConcurrent cisplatinII trialOropharynx cancerPrimary surgeryDose intensityIII trialsInstitutional seriesInvasive resectionMultimodality treatmentSystemic agentsSystemic therapyPrimary diseaseCure rateToxic therapiesMultimodality strategyContemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Maughan A, Sadigh K, Angulo-Diaz V, Mandimika C, Villanueva M, Lim JK, Ogbuagu O. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. BMC Infectious Diseases 2019, 19: 378. PMID: 31053098, PMCID: PMC6500032, DOI: 10.1186/s12879-019-3974-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAminoisobutyric AcidsAnti-Retroviral AgentsAntiviral AgentsBenzimidazolesCarbamatesCoinfectionCyclopropanesDrug InteractionsFemaleHepacivirusHepatitis CHeterocyclic Compounds, 4 or More RingsHIV InfectionsHumansLactams, MacrocyclicLeucineLiver CirrhosisMaleMiddle AgedProlinePyrrolidinesQuinoxalinesSofosbuvirSulfonamidesTreatment OutcomeViral LoadConceptsHIV-HCVExclusion criteriaClinical trialsHIV-HCV co-infected patientsNew hepatitis C treatmentsHepatitis C virus infectionCo-infected patientsHIV patient populationC virus infectionGlecaprevir/pibrentasvirSofosbuvir/velpatasvirExcellent cure ratesHIV viral loadMajority of patientsHepatitis C treatmentInjection drug useReal-world populationART regimenHCV agentsCurrent regimensDecompensated cirrhosisViral loadPangenotypic activityCure ratePatient populationAn Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study.
Tsay C, Kim S, Norwich-Cavanaugh A, Hsia HC, Narayan D. An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study. Annals Of Plastic Surgery 2019, 82: s199-s201. PMID: 30855388, DOI: 10.1097/sap.0000000000001840.Peer-Reviewed Original ResearchConceptsTopical imiquimodNeck melanomaSurgical excisionCure rateAtypical squamous cell carcinomaComparable cure ratesSquamous cell carcinomaDuration of treatmentLength of treatmentFrequency of treatmentStage T1aActive inflammationStandard therapyInitial biopsyResidual inflammationPatient adherencePositive marginsResidual diseaseCell carcinomaCertain patientsSkin biopsiesComplete excisionFunctional impairmentInclusion criteriaDifficult lesions
2018
Why Travel for Complex Cancer Surgery? Americans React to ‘Brand-Sharing’ Between Specialty Cancer Hospitals and Their Affiliates
Chiu AS, Resio B, Hoag JR, Monsalve AF, Blasberg JD, Brown L, Omar A, White MA, Boffa DJ. Why Travel for Complex Cancer Surgery? Americans React to ‘Brand-Sharing’ Between Specialty Cancer Hospitals and Their Affiliates. Annals Of Surgical Oncology 2018, 26: 732-738. PMID: 30311158, DOI: 10.1245/s10434-018-6868-9.Peer-Reviewed Original ResearchConceptsComplex cancer surgeryCancer HospitalCancer surgerySmall hospitalsSurgical careLocal hospitalSpecialty cancer hospitalComplex surgical careSmall local hospitalsMethodsA nationalResultsA totalCure rateGuideline complianceSurgical safetyComplex surgeryAffiliate hospitalsHospitalSurgeryLarge hospitalsHospital networkCareAmerican adultsSafetyMotivated respondentsRespondentsProtocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Lawrence NJ, Chan H, Toner G, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Mazhar D, Pashankar F, Frazier L, McDermott R, Walker R, Tan H, Davis ID, Grimison P, on behalf of ANZUP. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer 2018, 18: 854. PMID: 30157803, PMCID: PMC6114870, DOI: 10.1186/s12885-018-4745-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinClinical ProtocolsClinical Trials, Phase III as TopicEtoposideFemaleHumansInfantInfant, NewbornMaleMulticenter Studies as TopicNeoplasms, Germ Cell and EmbryonalRandomized Controlled Trials as TopicResearch DesignYoung AdultConceptsPoor-risk metastatic germ cell tumoursMetastatic germ cell tumorsGerm cell tumorsStandard BEP chemotherapyFirst-line chemotherapyCell tumorsLine chemotherapyBEP chemotherapyCure rateClinical trialsPoor-risk germ cell tumorsMulticentre phase 2 trialRandomised phase 3 trialStandard first-line treatmentPhase 3 clinical trialsComplete response rateFirst-line treatmentPhase 2 trialPhase 3 trialProgression-free survivalHealth-related qualityPediatric age groupFemale participantsInternational multicentreStandard BEP
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply